1. Lie HR, LagergrenJ, Rasmussen F, et al. Bowel and bladder control of children with myelomeningocele: a nordic study. Dev Med Child Neurol.. 1991;33: 1053-1061.
2.
2. Fernandes ET, Reinberg Y, Vernier R, et al. Neurogenic bladder dysfunction in children: review of pathophysiology and current management. J Pediatr.1994;124: 1-7.
4. Malone PS, Wheeler RA, Williams JE. Continence in patients with spina bifida: long term results. Arch Dis Child. 1994;70: 107-110.
5.
5. LapidesJ, Diokno AC, Silber SJ, et al. Clean, intermittent self-catheterization in the treatment of urinary tract disease.J Urol.. 1972;107:458-461.
6.
6. Cole AT, Fried FA. Favorable experiences with imipramine in the treatment of neurogenic bladder. J Urol.. 1972;107: 44-45.
7.
7. Raezer DM, Benson GS, Wein AJ, et al. The functional approach to the management of the pediatric neuropathic bladder: a clinical study. J Urol.. 1977;117:649-654.
8.
8. Harris D, Risebrough N. Continence and independence in children with neurogenic bowel and bladder dysfunction: family perceptions. Dev Med Child Neurol.. 1997;39 (Suppl 75):11-11.
9.
9. Wein AJ. Pharmacological options for the overactive bladder. Urology.. 1998;51 (Suppl 2A):43-47.
10.
10. Benson GS, Sarshik SA, Raezer DM, et al. Bladder muscle contractility: comparative effects and mechanism of action of atropine, propantheline, flavoxate, and imipramine. Urology.. 1977;9: 31-35.
11.
11. BiggerJTJr, Giardina EGV, Perel JM, et al. Cardiac antiarrythmic effect of imipramine hydrochloride. N EnglJ Med. 1997;296: 206-207.
12.
12. Olubadewo J. The effect of imipramine on rat detrusor muscle contractility. Arch Int Pharmacodyn Ther.. 1980;245: 84-94.
